BRK.B 7.98PLUS 2.01TGTX -0.04LLY 35.94SU.TO -2.48CASH 0LRCX -30.66IBM 0.65
Merck & Company (MRK)

NYSE:MRK

Merck & Company (MRK)

147.24
-2.64 (1.76%)
as of Oct 22, 2026, 8:00:00 pm Market Closed.
311 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
BUY

Merck & Company(MRK)

Jan 06, 2004
Has had problems with patent expiry's and drugs in its channel. Gives a 3% dividend yield. Continues to like.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$47.77

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
TOP PICK

Merck & Company(MRK)

Dec 23, 2003
trading at significantly less than fair value. Bad news on drug development. Dividends at 3.3%
Photo of Peter Arender, CFAPeter Arender, CFA
Owned
Unlock Rating
$44.77

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Dec 05, 2003
Have had tremendous issues. They had to stop production on a couple of drugs that were being tested. Virtually no revenue or earnings coming.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$43.07

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Dec 03, 2003
When the stock is not participating in a bull market, steer clear. A strong Company and well financed with good products but there is no real excitement. If the market rolls over, it would get hit hard.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$43.63

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Nov 13, 2003
Likes some of the major pharmaceuticals at these levels. Very cheap. Buy and hold.
Photo of John ZechnerJohn ZechnerUnlock Rating
$45.80

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
STRONG BUY

Merck & Company(MRK)

Nov 11, 2003
A fantastic time to be buying this stock. If the pharmaceutical industry reverts to anything near normal, this is a huge screaming buy.
Photo of Peter Arender, CFAPeter Arender, CFA
Owned
Unlock Rating
$43.87

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Nov 06, 2003
Missed its numbers. Demographics for drugs looks great. At a great price.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$43.60

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Sep 03, 2003
Not a fan. They don't have a very strong pipeline of promising drugs. Present drugs are facing competition from generics.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$50.68

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Merck & Company(MRK)

Aug 05, 2003
Trading at a significant discount.Has been getting left behind.
Photo of Peter Arender, CFAPeter Arender, CFAUnlock Rating
$53.51

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Merck & Company(MRK)

Jul 23, 2003
(Was a top pick on May 21/03. Up 4.4%.) Still likes. Offers good value.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$57.89

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Merck & Company(MRK)

Jun 02, 2003
2.5% dividend. Big name products. Only 14/15 X next years earnings. Recent studies suggest that some of their drugs may also be useful in preventing cancer.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$55.73

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Merck & Company(MRK)

May 21, 2003
Trading at 16 X earnings, yielding 2.6%. Great pipeline of new drugs. Great balance sheet.
Photo of Laura WallaceLaura WallaceUnlock Rating
$55.38

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Mar 24, 2003
Good price. Good earnings price momentum.
Photo of Peter Arender, CFAPeter Arender, CFAUnlock Rating
$54.65

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Merck & Company(MRK)

Feb 04, 2003
Health care sector is a good sector. 15/16 PE. Good price.
Photo of Peter Arender, CFAPeter Arender, CFAUnlock Rating
$54.85

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Merck & Company(MRK)

Jan 02, 2003
Some of their drugs have come off patent and they are having difficulty with Research /Development productivity. Prefers Pfizer.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$58.25

Stock price when the opinion was issued

$147.24

As of Oct 22, 2026. Market Open.

biotechnologypharmaceutical
Showing 271 to 285 of 313 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

PSLV.TO -1.53$24.7
EME -38.76$660.41
COPX -4.89$73.13
CDWC 0$
MSFT -11.87$521.08

Today's Top Picks

BRK.B 7.98$546.97
PLUS 2.01$96.15
TGTX -0.04$53.16
LLY 35.94$1306.69
SU.TO -2.48$108.39

Popular Articles

Latest Sell Signals

TSM -19.54$412.35
PFE 0.57$30.42
WSP.TO 8.6$182.75
ITA -1.31$204.48
HWM -14.86$193.29

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

David Burrows

David Burrows

Barometer Capital Management

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Karen Firestone, CEO, Aureus Asset Management

Karen Firestone, CEO, Aureus Asset Management

Aureus Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like